SEPN
Septerna, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.10B
P/E Ratio
—
EPS
$-1.10
Beta
—
52W High
$32.63
52W Low
$5.12
50-Day MA
$26.17
200-Day MA
$20.66
Dividend Yield
—
Profit Margin
-106.40%
Forward P/E
107.53
PEG Ratio
—
About Septerna, Inc. Common Stock
Septerna, Inc. is an innovative biotechnology company at the forefront of developing transformative therapeutics via selective protein modulation. With a commitment to addressing unmet medical needs across diverse disease areas, Septerna leverages proprietary platforms and deep scientific acumen to advance a robust pipeline of next-generation drug candidates. The company's strategic focus on research and development, coupled with its potential for significant clinical impact, positions it as a compelling opportunity for institutional investors seeking exposure in the dynamic biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | $45.95M |
| Gross Profit (TTM) | $45.95M |
| EBITDA | $-79.19M |
| Operating Margin | -66.40% |
| Return on Equity | -12.20% |
| Return on Assets | -9.59% |
| Revenue/Share (TTM) | $1.04 |
| Book Value | $8.52 |
| Price-to-Book | 2.96 |
| Price-to-Sales (TTM) | 23.93 |
| EV/Revenue | 16.61 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 11276.00% |
| Shares Outstanding | $44.91M |
| Float | $22.90M |
| % Insiders | 3.14% |
| % Institutions | 102.96% |
Analyst Ratings
Consensus ($44.43 target)
1
Strong Buy7
BuyData last updated: 4/9/2026